Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes

被引：0
|
作者：
Edith M. Heintjes
Trine L. Thomsen
Fernie J. A. Penning-van Beest
Torsten E. Christensen
Ron M. C. Herings
机构：
[1] PHARMO Institute,Department of Health Policy & Management
[2] Novo Nordisk A/S,undefined
[3] Erasmus University Rotterdam,undefined
来源：
Advances in Therapy | 2010年 / 27卷
关键词：
dose; glycemic control; HbA1c; insulin detemir; insulin glargine; retrospective cohort study; type 2 diabetes; utilization;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：211 / 222
页数：11
相关论文
共 50 条
  • [1] Glycemic Control and Long-Acting Insulin Analog Utilization in Patients with Type 2 Diabetes
    Heintjes, Edith M.
    Thomsen, Trine L.
    Penning-van Beest, Fernie J. A.
    Christensen, Torsten E.
    Herings, Ron M. C.
    [J]. ADVANCES IN THERAPY, 2010, 27 (04) : 211 - 222
  • [2] Treatment of Type 1 and Type 2 Diabetes Mellitus with Insulin Detemir, a Long-Acting Insulin Analog
    Young, Jason R.
    McAdam-Marx, Carrie
    [J]. CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2010, 3 : 65 - 80
  • [3] Mechanism for the Differential Effect of the Long-Acting Insulin Analog Detemir on Weight in Patients with Type 2 Diabetes
    Sheldon, Ben
    Alsini, Najlaa
    Zachariah, Sunil
    Shojaee-Moradie, Fariba
    Bodinham, Caroline
    Robertson, Denise
    Bell, Jimmy
    Thomas, Louise
    Vidal, Hubert
    Meugnier, Emmanuelle
    Jones, Richard H.
    Umpleby, A. M.
    Russell-Jones, David
    [J]. DIABETES, 2011, 60 : A263 - A264
  • [4] LY307161 SR, a long-acting GLP-1 analog, improved glycemic control in patients with type 2 diabetes
    Trautmann, M
    Chen, CF
    Chappell, J
    Dananberg, J
    Patterson, B
    Klausmann, G
    Kapitza, C
    [J]. DIABETES, 2003, 52 : A136 - A136
  • [5] The utilization of long-acting insulin analogues and intermediate-acting NPH insulin among patients with type 2 diabetes in the United Kingdom
    Brunetti, Vanessa C.
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 404 - 404
  • [6] LY307161 SR, a long-acting GLP-1 analog, improved glycemic control in patients with Type 2 diabetes.
    Trautmann, ME
    Chen, CF
    Chappell, JC
    Dananberg, J
    Patterson, B
    Klausmann, G
    Kapitza, C
    [J]. DIABETOLOGIA, 2003, 46 : A63 - A63
  • [7] UTILIZATION PATTERNS AND HYPOGLYCEMIA IN PATIENTS WITH TYPE-2 DIABETES ON CONCOMITANT EXENATIDE AND LONG-ACTING INSULIN THERAPY
    Wade, R.
    Quimbo, R. A.
    Fabunmi, R.
    Blickensderfer, A. L.
    Pawaskar, M. D.
    Misurski, D.
    [J]. VALUE IN HEALTH, 2009, 12 (03) : A99 - A99
  • [8] Mechanism for the differential effect of the long-acting insulin analog detemir on weight in patients with type 1 diabetes
    Zachariah, S.
    Sheldon, B.
    Shojaee-Moradie, E.
    Jackson, N.
    Backhouse, K.
    Johnsen, S.
    Umpleby, M.
    Russell-Jones, D.
    [J]. DIABETOLOGIA, 2010, 53
  • [9] An update on the treatment of type 1 and type 2 diabetes mellitus: focus on insulin detemir, a long-acting human insulin analog
    Raslova, Katarina
    [J]. VASCULAR HEALTH AND RISK MANAGEMENT, 2010, 6 : 399 - 410
  • [10] The Comparative Dosing and Glycemic Control of Intermediate and Long-Acting Insulins in Adult Patients With Type 1 and 2 Diabetes Mellitus
    Kabakov, Anna
    Merker, Andrew
    [J]. JOURNAL OF PHARMACY TECHNOLOGY, 2022, 38 (01) : 46 - 53
12345